We previously demonstrated a change in the receptors mediating 5-hydroxytryptamine (5-HT)-induced contraction in arteries of deoxycorticosterone acetate (DOCA)-salt-hypertensive rats. Specifically, contraction to 5-HT is mediated primarily by 5-HT_2A receptors in arteries from normotensive sham rats and by both 5-HT_2A and 5-HT_2B receptors in arteries from hypertensive rats. We hypothesized that the 5-HT_2B receptor may play a role in maintaining the high blood pressure of DOCA-salt-hypertensive rats, and herein we provide data connecting in vitro and in vivo findings. The endothelium-denuded isolated superior mesenteric artery of DOCA-salt rats displayed a marked increase in maximum contraction to the newly available 5-HT_2B-receptor agonist BW-723C86 compared with that of arteries from sham rats, confirming that the 5-HT_2B receptor plays a greater role in 5-HT-induced contraction in arteries from DOCA-salt rats. In chronically instrumented rats, the 5-HT_2B-receptor antagonist LY-272015 (0.3, 1.0, and 3.0 mg/kg iv at 30-min intervals) was given cumulatively 1 time/wk during 4 wk of continued DOCA-salt treatment. LY-272015 did not reduce blood pressure of the sham-treated rats at any time or dose. However, LY-272015 (1.0 and 3.0 mg/kg) significantly reduced mean blood pressure in a subgroup of week 3 (20 mmHg) and week 4 DOCA-salt (40 mmHg) rats that had extremely high blood pressure (mean arterial blood pressure ~200 mmHg). Blockade of 5-HT_2B receptors by in vivo administration of LY-272015 (3.0 mg/kg) was verified by observing reduced 5-HT-induced contraction in rat stomach fundus, the tissue from which the 5-HT_2B receptor was originally cloned. These data support the novel hypothesis that 5-HT_2B-receptor expression is induced during the development of DOCA-salt hypertension and contributes to the maintenance of severe blood pressure elevations.

5-hydroxytryptamine; deoxycorticosterone acetate; experimental hypertension; vasoconstriction; serotonin receptors

This article has been cited by other articles:

				S. W. Watts The love of a lifetime: 5-HT in the cardiovascular system Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R252 - R256. [Abstract] [Full Text] [PDF]

				S. W. Watts The beginning of a fantastic, unanswered question: is 5-HT involved in systemic hypertension? Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H915 - H916. [Abstract] [Full Text] [PDF]

				J. Diaz, W. Ni, J. Thompson, A. King, G. D. Fink, and S. W. Watts 5-Hydroxytryptamine Lowers Blood Pressure in Normotensive and Hypertensive Rats J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 1031 - 1038. [Abstract] [Full Text] [PDF]

				W. Ni, K. Lookingland, and S. W. Watts Arterial 5-Hydroxytryptamine Transporter Function Is Impaired in Deoxycorticosterone Acetate and N{omega}-Nitro-L-Arginine But Not Spontaneously Hypertensive Rats Hypertension, July 1, 2006; 48(1): 134 - 140. [Abstract] [Full Text] [PDF]

				A. Russell, A. Banes, H. Berlin, G. D. Fink, and S. W. Watts 5-Hydroxytryptamine2B Receptor Function Is Enhanced in the Nomega -Nitro-L-arginine Hypertensive Rat J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 179 - 187. [Abstract] [Full Text] [PDF]

				S. W. Watts Serotonin-Induced Contraction in Mesenteric Resistance Arteries: Signaling and Changes in Deoxycorticosterone Acetate-Salt Hypertension Hypertension, March 1, 2002; 39(3): 825 - 829. [Abstract] [Full Text] [PDF]

				J. A. Florian, A. Dorrance, R. C. Webb, and S. W. Watts Mineralocorticoids upregulate arterial contraction to epidermal growth factor Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R878 - R886. [Abstract] [Full Text] [PDF]